• Bacteroides fragilis and Gut–Brain Cholinergic Signaling

  2026-09-09

  A 2026 Neuron study identifies a colonic ChAT-positive cell–vagus–brain circuit through which Bacteroides fragilis suppresses seizures in mouse models and shows efficacy in pediatric refractory epilepsy. Its combination of microbiota analysis, neural recordings, pharmacological blockade, chemogenetics, and randomized clinical testing provides a mechanistic framework for microbiota-targeted antiseizure research.

• Tetracycline Hydrochloride: Assay Logic

  2026-09-09

  Tetracycline Hydrochloride is more than a routine bacteriostatic antibiotic: its ribosome-centered activity demands carefully matched endpoints, controls, and solvent handling. This guide develops an assay-design framework and contrasts bacterial translation inhibition with ROS-driven cancer-cell death without conflating the two mechanisms.

• Alfuzosin HCl: Mechanism and BPH Research

  2026-09-08

  Alfuzosin HCl is a functionally uroselective α1 adrenoceptor antagonist that reduces prostate, bladder-neck, and urethral smooth-muscle tone in benign prostatic hyperplasia. Its clinical pharmacology, formulation parameters, solubility, and assay ranges support both translational and analytical BPH research.

• Annexin V-APC/7-AAD Apoptosis Kit: Read Death in Context

  2026-09-08

  The Annexin V-APC/7-AAD Apoptosis Kit converts phosphatidylserine exposure and membrane failure into an interpretable cell-death map. This article connects the assay to PAD4–NET cancer research while defining what apoptosis detection can—and cannot—prove.

• Fasting, Translatome Remodeling, and Tumorigenesis

  2026-09-07

  Yang et al. identify phosphorylation of eIF4E as a selective translational control mechanism that enables hepatic ketogenesis during fasting and ketogenic feeding. The study connects fatty-acid sensing through the AMPK–MNK–eIF4E pathway to diet-dependent pancreatic tumor growth, providing a mechanistic basis for combining dietary intervention with translational inhibition.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-09-07

  Lutomski and colleagues developed a native mass-spectrometry workflow that releases membrane proteins and signaling complexes directly from retinal rod disc membranes, preserving proteoform-specific interaction information. The study shows that lipid modifications and proteoform identity influence rhodopsin-associated assemblies and the off-target binding of vardenafil and sildenafil to PDE6, providing a framework for more discriminating drug-screening assays.

• Temozolomide: Mechanism-Led Glioma Assays

  2026-09-05

  Temozolomide is a small-molecule alkylating agent for DNA damage, DNA repair mechanism research, and glioma models. This article develops a genotype-aware assay strategy based on ATRX status, combination design, and rigorous interpretation of chemotherapy resistance data.

• 5-Azacytidine Reprograms Dormant Cells to Block Metastasis

  2026-09-04

  Singh et al. show that 5-Azacytidine combined with retinoic acid agonism can reprogram disseminated cancer cells into a stable, non-proliferative state rather than merely eliminating them. The study links metastasis suppression to restoration of TGF-β–SMAD4 signaling and provides a framework for evaluating epigenetic control of cancer dormancy.

• N4-Acetylcytidine: From Structure to Strategy

  2026-09-04

  A mechanistic and translational guide to using N4-Acetylcytidine as a defined ac4C nucleoside substrate, analytical reference, and control in RNA epigenetics research.

• Taihangia rupestris: UPLC-MS/MS and Bioactivity

  2026-09-03

  This 2026 RSC Advances study combines UPLC-MS/MS profiling, complementary antioxidant tests, α-glucosidase inhibition, activity-guided screening, and molecular docking to compare wild and cultivated Taihangia rupestris leaves. Foothill cultivation produced the strongest chemical and functional profile, supporting conservation-oriented cultivation while identifying flavonoids and phenolics as priorities for further natural-product research.

• GS-441524: Designing Matrix-Aware Antiviral Assays

  2026-09-03

  GS-441524 research is most informative when parent compound, released nucleoside, and downstream active metabolite are measured together. This article develops a matrix-aware assay strategy from recent LC–MS/MS evidence, with practical guidance for antiviral and pharmacokinetic studies.

• NSP15 Screening Identifies Thymopentin and Oleuropein

  2026-09-02

  The 2021 reference study used structure-based virtual screening and molecular dynamics to prioritize natural products against the SARS-CoV-2 NSP15 endoribonuclease. Thymopentin and oleuropein formed the most favorable and dynamically stable computational complexes, but biochemical and cellular validation remains necessary before interpreting them as antiviral inhibitors.

• IDH2 Reprogramming Drives CRC Through HIF-1α

  2026-09-02

  The reference study identifies mitochondrial IDH2 as a metabolic driver of colorectal cancer progression, linking reductive TCA cycle activity to ATP production, glycolysis, and HIF-1α signaling. Its combined genetic, pharmacological, cellular, and in vivo evidence suggests that IDH2-dependent α-ketoglutarate handling is a potential metabolic vulnerability, while also defining experiments needed to separate energy failure from direct control of HIF-1α turnover.

• Aβ42 Fibrils Activate Microglial Phagocytosis

  2026-09-01

  Kopec and Carroll showed that fibrillar Amyloid β-Peptide (1-42) stimulates murine microglial phagocytosis in a time- and dose-dependent manner. Their multi-cargo flow-cytometry design linked Aβ42 aggregation state, persistence after peptide removal, and proteoglycan-dependent regulation to a broader model of amyloid-driven innate immune activation.

• Otilonium Bromide: Applied Research Workflows

  2026-09-01

  Otilonium Bromide provides a practical antimuscarinic perturbation tool for cholinergic signaling, smooth muscle contractility, and receptor-mediated cellular assays. This workflow-focused guide covers stock preparation, controls, concentration planning, troubleshooting, and responsible translation of structure-based screening concepts.

7938 records 1/530 page Next 12345 下5页 Last page